(New York, NY) – Stockhouse.com announces the release of its newest issue of Ticker Trax, an investment report written by Thom Calandra. This report reveals a special focus on BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), a developer of the anti-viral peramivir, which was identified in December 2008 as a ‘Top Portfolio Prospect’ for subscribers in the life sciences component of the Ticker Trax portfolio. The recent influenza outbreaks saw shares of BioCryst gain nearly 140% this week alone, leaving many wondering what’s next for this dynamic stock.
As international media focused on swine flu, investors late last week began looking at pharmaceutical companies as investment opportunities. Some pharmaceutical companies already have anti-viral compounds headed to outbreak sites in Mexico and elsewhere.
Thom Calandra describes the sudden move as “a manic reaction to an evolving series of events” and cautions speculators to steer clear of all flu-related companies. “Some companies are deserving of a premium for the possibility of a pandemic, but placing a monetary value on that is difficult”, states Calandra.
In this latest issue of Ticker Trax, Calandra determines a fair-value price for the Company, given its drug discovery methods and a portfolio of candidates that address influenza, psoriasis, leukemia and cardiac arrest.
Excerpt: Ticker Trax “The crystallography ball” April 29, 2009
How does one arrive at a potential fair value for a life sciences company such as BioCryst? Not easy, especially if one is, as I am, a story person more than a quantitative analyst. I believe in products, or future products. I also believe life-sciences deserves to be at least 20 percent of a high-risk portfolio. The Kleiner Perkins Global Preparedness Fund has BioCryst as a central component -- at publicly traded prices in the teens.
With almost 40 million shares outstanding, BioCryst at present is worth about $140 million, perhaps more fully diluted. Yet one can make a case for BioCryst one day becoming a mini-Amgen. I can see BioCryst’s market worth growing into…Find out more at Ticker Trax.
Ann-Marie Fleming
Stockhouse Inc.
Ph: 604.331.0995 or 1.800.650.1211
ann-marie.fleming@
